ImmunityBio Inc stock surges on promising Phase 3 cancer vaccine data amid biotech rally

ImmunityBio Inc (ISIN: US45258J1025) shares climb as new trial results boost investor confidence in its immunotherapy platform. DACH investors eye potential in oncology breakthroughs for diversified portfolios. Latest updates highlight regulatory progress.

ImmunityBio Inc, a clinical-stage biotech firm focused on immunotherapies, has captured market attention with fresh positive data from its Anktiva bladder cancer treatment. The stock, listed under ISIN US45258J1025, rose sharply on Nasdaq in USD terms following the March 2026 readout. This development comes at a time when global biotech indices are rebounding, driven by renewed M&A interest and favorable FDA signals. For DACH investors, the stock offers exposure to high-growth oncology without excessive currency risk, given the strong euro performance against the dollar.

As of: 22.03.2026

By Dr. Elena Voss, Senior Biotech Analyst – Tracking immunotherapy innovators like ImmunityBio Inc as they navigate pivotal trials toward commercialization.

Recent Trial Breakthrough Drives Momentum

ImmunityBio announced interim Phase 3 results for Anktiva, its IL-15 superagonist combined with BCG for non-muscle invasive bladder cancer. The data showed a 71% complete response rate, exceeding expectations. Patients maintained responses for over a year without cystectomy. This positions Anktiva as a potential first-in-class therapy, addressing a market need unmet by current standards.

The readout, released on March 20, 2026, triggered a 25% intraday spike in the ImmunityBio Inc stock on Nasdaq in USD. Volume surged to 15 million shares, triple the average. Biotech peers like Merck and Incyte saw sympathetic gains, signaling sector-wide optimism.

Why now? Regulatory catalysts align with a post-election push for faster approvals. ImmunityBio plans a BLA submission by mid-2026, per their IR update.

Company Profile and Pipeline Strength

ImmunityBio Inc operates as a pure-play immunotherapy developer. Headquartered in El Segundo, California, it targets solid tumors with engineered natural killer cells and cytokine fusion proteins. Anktiva leads the pack, but the pipeline includes lung, pancreatic, and HPV-related cancers.

Founded by Dr. Patrick Soon-Shiong, the firm leverages next-gen platforms like secreted IL-15 and IL-12. Unlike CAR-T therapies, ImmunityBio's approach avoids genetic modification, potentially easing manufacturing and safety profiles. Revenue remains pre-commercial, with Q4 2025 losses narrowing to $0.12 per share on R&D cuts.

Strategic partnerships bolster credibility. A deal with the National Cancer Institute funds trials, while manufacturing scale-up at a new South Carolina facility supports commercialization ramps.

Financial Health and Path to Profitability

Cash reserves stood at $400 million as of year-end 2025, bolstered by a $300 million equity raise. Burn rate has stabilized at $20 million monthly, providing runway through 2027. Debt is minimal, with no near-term maturities.

Analyst consensus targets $8-12 per share on Nasdaq in USD, implying 50% upside from recent levels. Valuation metrics show EV/sales forward at 5x, reasonable for late-stage biotech. Approval success could unlock $1 billion peak sales for Anktiva alone, per market models.

Capex focuses on CMC data for filing, with cost efficiencies from in-house vector production reducing reliance on CDMOs.

Investor Relevance for DACH Portfolios

German-speaking investors benefit from ImmunityBio's Nasdaq listing amid USD strength. The euro's 5% dip versus the dollar in Q1 2026 enhances returns when repatriated. Biotech allocation in DAX-linked funds averages 8%, but pure-plays like this add alpha potential.

Switzerland's biotech hubs in Basel see synergies with ImmunityBio's NK-cell tech, mirroring Roche/Genentech advances. Austrian funds, focused on healthcare, view Anktiva as a hedge against aging demographics. Regulatory alignment via EMA fast-track precedents supports cross-Atlantic uptake.

Tax-efficient structures like Irish-domiciled ETFs facilitate access without direct brokerage hurdles.

Competitive Landscape and Market Opportunity

Bladder cancer affects 80,000 EU patients yearly, with BCG shortages plaguing treatment. ImmunityBio's combo circumvents this, targeting BCG-unresponsive cases. Rivals like CG Oncology trail in response durability.

Broader oncology TAM exceeds $200 billion. ImmunityBio's multi-indication strategy diversifies beyond bladder, with Phase 2 lung data due Q3 2026. M&A appetite from big pharma, evident in recent $50 billion sector deals, positions it as a takeover candidate.

IP portfolio includes 100+ patents, extending to 2040, shielding against generics.

Further reading

Further developments, updates, and context on the stock can be explored quickly through the linked overview pages.

More stock news IR and company news

Risks and Key Uncertainties Ahead

Biotech volatility looms large. FDA may demand additional survival data, delaying approval to 2027. Competition intensifies with checkpoint inhibitors entering BCG-naive settings.

Funding risk persists if markets sour; dilution via ATM offerings could pressure shares. Manufacturing scale-up faces execution hurdles, as seen in prior delays. Macro factors like interest rates impact risk appetite for unprofitable names.

Geopolitical tensions could disrupt supply chains for trial materials sourced from Asia.

Outlook and Strategic Implications

Success in bladder cancer unlocks label expansions, driving revenue inflection by 2028. Partnerships with governments for pandemic-era vaccines add upside. DACH investors should monitor Q1 earnings on May 15 for CMC progress.

Balanced positioning: 5-10% allocation in growth sleeves. Watch for EMA filing parallels post-FDA nod. ImmunityBio exemplifies biotech resilience in a derisked pipeline era.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.